Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR119 | Q8TDV5 | 11/20 | 0.48 |
| ▸ | HTT | P42858 | 1/20 | 0.46 |
| ▸ | P2RY14 | Q15391 | 1/20 | 0.44 |
| ▸ | TRPV3 | Q8NET8 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 2/20 | 0.44 |
| ▸ | CNR1 | P21554 | 1/20 | 0.44 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.44 |
| ▸ | GPR35 | Q9HC97 | 1/20 | 0.44 |
| ▸ | GPR55 | Q9Y2T6 | 1/20 | 0.44 |
| ▸ | HPGDS | O60760 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | THRB | P10828 | 1/20 | 0.43 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2062893 | 0.90 | GPR119 (0.51) | GPR119HTTTRPV3MAPTCNR1 | |
| SCHEMBL2063254 | 0.88 | CNR1 (0.54) | GPR119HTTTRPV3MAPTCNR1 | |
| SCHEMBL15732675 | 0.87 | PREP (0.43) | GPR119HTTTRPV3EPHX2 | |
| SCHEMBL16058214 | 0.87 | PREP (0.44) | GPR119TRPV3 | |
| SCHEMBL27797117 | 0.86 | P2RY14 (0.53) | GPR119HTTP2RY14MAPTHPGDS | |
| SCHEMBL6168833 | 0.86 | HTT (0.51) | GPR119HTTMAPTHPGDSKDM4E | |
| SCHEMBL3376376 | 0.86 | KMO (0.45) | — | |
| SCHEMBL15732676 | 0.84 | P2RY14 (0.47) | GPR119HTTP2RY14TRPV3MAPT | |
| SCHEMBL311477 | 0.84 | HPGDS (0.48) | GPR119HTTP2RY14MAPTHPGDS | |
| SCHEMBL15732681 | 0.83 | GPR119 (0.45) | GPR119HTTP2RY14TRPV3MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2755965-B1 | NOVEL IMIDAZOLE AMINES AS MODULATORS OF KINASE ACTIVITY | MERCK PATENT GMBH (DE) | 2017-07-26 | — | — | EP | disclosed |
| US-20160000785-A1 | Novel Imidazole Amines as Modulators of Kinase Activity | MERCK PATENT GMBH (DE) | 2016-01-07 | — | — | US | disclosed |
| US-9145392-B2 | Imidazole amines as modulators of kinase activity | MERCK PATENT GMBH (DE) | 2015-09-29 | — | — | US | disclosed |
| US-20140343029-A1 | Novel Imidazole Amines as Modulators of Kinase Activity | MERCK PATENT GMBH (DE) | 2014-11-20 | — | — | US | disclosed |
| EP-2755965-A1 | NOVEL IMIDAZOLE AMINES AS MODULATORS OF KINASE ACTIVITY | Merck Patent GmbH (DE) | 2014-07-23 | — | — | EP | disclosed |
| EP-2148880-B1 | P70 S6 KINASE INHIBITORS | LILLY CO ELI (US) | 2014-05-28 | — | — | EP | disclosed |
| CN-101679439-B | P70S 6 kinase inhibitors | LILLY CO ELI | 2013-09-11 | — | — | CN | disclosed |
| CN-102216302-B | Akt and p70 s6 kinase inhibitors | LILLY CO ELI | 2013-08-21 | — | — | CN | disclosed |
| WO-2013040059-A1 | NOVEL IMIDAZOLE AMINES AS MODULATORS OF KINASE ACTIVITY | MERCK PATENT GMBH (DE) | 2013-03-21 | — | — | WO | disclosed |
| US-8334293-B2 | P70 S6 kinase inhibitor and EGFR inhibitor combination therapy | ELI LILLY AND COMPANY (US) | 2012-12-18 | — | — | US | disclosed |
| WO-2010056574-A1 | P70 S6 KINASE INHIBITOR AND MTOR INHIBITOR COMBINATION THERAPY | ELI LILLY AND COMPANY (US) | 2010-05-20 | — | — | WO | disclosed |
| WO-2010056563-A1 | AKT AND P70 S6 KINASE INHIBITORS | ELI LILLY AND COMPANY (US) | 2010-05-20 | — | — | WO | disclosed |
| US-20100120801-A1 | AKT AND P70 S6 KINASE INHIBITORS | ELI LILLY AND COMPANY | 2010-05-13 | — | — | US | disclosed |
| US-20100120801-A1 | AKT AND P70 S6 KINASE INHIBITORS | ELI LILLY AND COMPANY | 2010-05-13 | — | — | US | disclosed |
| US-20100120801-A1 | AKT AND P70 S6 KINASE INHIBITORS | ELI LILLY AND COMPANY | 2010-05-13 | — | — | US | disclosed |
| CN-101679439-A | P70S 6 kinase inhibitors | LILLY CO ELI | 2010-03-24 | — | — | CN | disclosed |
| EP-2148880-A1 | P70 S6 KINASE INHIBITORS | ELI LILLY AND COMPANY (US) | 2010-02-03 | — | — | EP | disclosed |
| US-20090163714-A1 | P70 S6 KINASE INHIBITORS | ELI LILLY AND COMPANY | 2009-06-25 | — | — | US | disclosed |
| WO-2009023515-A2 | REACTORS AND METHODS FOR PROCESSING REACTANTS THEREIN | ELI LILLY AND COMPANY (US) | 2009-02-19 | — | — | WO | disclosed |
| WO-2008140947-A1 | P70 S6 KINASE INHIBITORS | ELI LILLY AND COMPANY (US) | 2008-11-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100120801-A1 | AKT AND P70 S6 KINASE INHIBITORS | RPS6KA6, RPS6KA1, MTOR | GPR119 1116/4885HTT 1836/4885P2RY14 2781/4885 |
| US-20160000785-A1 | Novel Imidazole Amines as Modulators of Kinase Activity | MAP3K11, MAP3K20, MAP3K19 | GPR119 715/4885HTT 4478/4885P2RY14 2857/4885 |
| US-20090163714-A1 | P70 S6 KINASE INHIBITORS | RPS6KA6, RPS6KA1, RPS6KA2 | GPR119 645/4885HTT 1029/4885P2RY14 2759/4885 |
| US-20140343029-A1 | Novel Imidazole Amines as Modulators of Kinase Activity | MAP3K11, MAP3K20, MAP3K19 | GPR119 715/4885HTT 4478/4885P2RY14 2857/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.